Universidad de Colima
Quick facts
Marketed products
- Oral Electrolytes
- Probiotic (Lactobacillus reuteri Prodentis · Dentistry / Oral Health
Lactobacillus reuteri Prodentis is a probiotic strain that colonizes the oral cavity and produces antimicrobial compounds to inhibit pathogenic bacteria and reduce oral inflammation.
Phase 3 pipeline
- ketamine sedation versus midazolam sedation · Anesthesiology
Ketamine acts as an NMDA receptor antagonist, blocking the action of glutamate in the brain.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Universidad de Colima
What are Universidad de Colima's marketed drugs?
Top marketed products include Oral Electrolytes, Probiotic (Lactobacillus reuteri Prodentis.
What is Universidad de Colima's pipeline?
Universidad de Colima has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include ketamine sedation versus midazolam sedation.
Related
- Oral Electrolytes
- Probiotic (Lactobacillus reuteri Prodentis · Dentistry / Oral Health
- Sector hub: All tracked pharma companies